Pfizer plans to file for full FDA approval of the Covid vaccine

Pfizer plans to file for full FDA approval of the Covid vaccine

May 5, 2021: -On Tuesday, Pfizer said it plans to file for full U.S. approval of its Covid-19 vaccine with German drugmaker BioNTech at this month-end. The company will be able to market the shot directly to consumers if the company signs off.

According to Pfizer, first-quarter sales of its Covid-19 vaccine was $3.5 billion, nearly 24% of its revenue for the quarter in its earnings report. It reported earnings and revenue were over Wall Street’s expectations.

The company expects full-year sales of $26 billion from the vaccine, up from its last forecast of nearly $15 billion. An adjusted pretax profit in the high 20% range of revenue for the vaccine is expected.

According to the earnings report, revenue from Pfizer’s oncology, internal medicine, hospital, and rare disease units rose by double digits during the quarter. The company’s inflammation and immunology unit generated around $1 billion in sales, a 9% rise from the previous year.

The company received U.S. approval of its Covid vaccine in December. Pfizer distributed millions of doses to the U.S. since then, intending to deliver 300 million doses by July-end.

Usually, it takes the Food and Drug Administration almost a year or more than that to determine if a drug is safe and effective for use in the general public. Due to the coronavirus pandemic, which has killed nearly 600,000 people in the United States, the FDA permitted using the shots under an Emergency Use Authorization.

The authorization permits conditional approval depending on two months of data. It’s not the same as a Biologic License Application, in which six months of data and secures full support is needed.

According to a slide presentation that accompanied the earnings release of the company, the company also said it is expecting to apply for a EUA for a booster shot that could protect against Covid variants in late July. It intends to apply for authorization for its vaccine for use in younger children in September and infants in November.

On April 1, Pfizer and BioNTech made an announcement that new data from their clinical trial showed their two-dose vaccine was safe and over 91% effective after the second dose.

At the time, Pfizer CEO Albert Bourla said the new data positions the companies “to submit a Biologics License Application to the U.S. FDA.”

If the vaccine is approved fully, it sets the stage for Pfizer and BioNTech to start advertising the shots directly to consumers and change the prices. It also allows the shots to stay on the market once the pandemic is over and the U.S. is no longer considered an “emergency.”

About Us

We provide the insights on leaders who are responsible for taking their organization to new heights, all the while bringing together a group of talented individuals.

Recent Posts

CalFoods Logistics | Making A Difference for those in Need | Steve Linkhart

Steve Linkhart, CEO of CalFoods Logistics, believes that he possesses one quality that sets the tone for CalFoods Logistics. “When we hire a new team member, there are clear responsibilities that need to be accomplished. Once we hire, train, and let that person take the ownership of the job, we allow them to do their job,” he explains. “We are always there to assist of course, but I feel that people get a sense of ownership of their role when they are allowed to do so. Everyone has a role from being CEO to pulling or entering orders, everyone has their unique responsibilities, and the foundation is always customer service, without that, everything after is on shaky ground.” Steve feels that there isn’t a role here too big or too small for anyone to jump in and help. He has unloaded his fair share of trucks and pulled orders over the past 18 months and will be glad to do it again if needed. “Taking care of our team is of the utmost importance to me. We offer a living wage, amazing benefits, and time off for the team to have a good work/life balance.”

Innovana Solutions | Leading with Determination & Commitment | Mitch McDermid

When Mitch McDermid launched Innovana, he had an evident vision of what he wanted the company to look like and what it could offer that was different from existing IT services and consulting firms. There was a clear need for a cloud-based services and business automation solutions provider that would address the needs of SMBs both from a pricing and service standpoint in Canada. Mitch and his team have been laser-focused on serving that niche.

Arete Wealth | Offering Excellence & Virtue | Joshua D. Rogers

A forward thinker, Joshua D. Rogers is always focused on the future. His vision was to introduce a smart, sophisticated approach to investing and wealth building. Since founding Arete Wealth in 2007, he’s done just that. Joshua’s brought an endowment-style of asset allocation to a broader audience of investors. From hedge funds to bespoke investments, his dream was to bring a new perspective to investing. Arete Wealth is the embodiment of that vision: a dynamic, energetic, comprehensive wealth management firm focused on the future.

OnView Integrated Solutions | The Guardian Angel | Joel Anaya

Joel Anaya, CEO of OnView Integrated Solutions, has been instrumental in building the company from the ground up. His innovation and vision transformed the way the company has scaled its business. OnView is a security provider bringing proactive solutions specifically designed to deter suspicious behavior in real-time before the crime occurs.